Company intelligence / Profile preview

Hirschfeld Oncology

Bethesda, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Hirschfeld Oncology is a clinical-stage biotechnology company specializing in the development of therapies that target the tumor microenvironment, specifically hypoxia-driven pathways. Founded by Dr. Steven Hirschfeld, a former FDA and NIH official, the company focuses on repurposing and optimizing small molecules to treat aggressive cancers like glioblastoma and renal cell carcinoma. Its lead candidate, HO-101, is a small molecule inhibitor of Hypoxia-inducible factor 1-alpha (HIF-1a) designed to disrupt tumor growth and angiogenesis. The company's approach combines deep regulatory insight with innovative clinical trial designs to accelerate the delivery of new treatments to patients.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Hirschfeld Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hirschfeld Oncology.

Explore the full profile